Table 1 Patients’ characteristics according to AKI
From: Acute kidney injury in patients with SARS-CoV-2 infection
Overall | No AKI | AKI | p value | |
|---|---|---|---|---|
n = 100 | n = 19 | n = 81 | ||
Age (year) | 59 [53–67] | 54 [45–61] | 60 [54–68] | 0.05 |
Male gender | 70 (70%) | 11 (58%) | 59 (73%) | 0.32 |
Absence of underlying comorbidity | 15 (15%) | 6 (32%) | 9 (11%) | 0.06 |
Chronic Obstructive Pulmonary Disease | 2 (2%) | 0 (0) | 2 (3%) | 1.00 |
Asthma | 8 (8%) | 2 (11%) | 6 (8%) | 1.00 |
History of hypertension | 56 (56%) | 8 (42%) | 48 (60%) | 0.25 |
Diabetes | 30 (30%) | 3 (16%) | 27 (34%) | 0.21 |
Immunocompromized | 26 (26%) | 4 (21%) | 22 (28%) | 0.78 |
Heart failure | 15 (15%) | 0 (0) | 15 (19%) | 0.09 |
Chronic kidney disease | 29 (29%) | 2 (11%) | 27 (33%) | 0.09 |
Body Mass Index (Kg/m2) | 28 [24–31] | 26 [23–31] | 28 [24–31] | 0.48 |
Obesity and overweight | 0.37 | |||
Overweight | 25 (25%) | 3 (16%) | 22 (27%) | |
Obese | 21 (21%) | 3 (16%) | 18 (22%) | |
Other | 54 (54%) | 13 (68%) | 41 (51%) | |
Chronic use of ACE/ARB | 30 (30%) | 3 (16%) | 27 (33%) | 0.22 |
Baseline serum creatinine (µmol/L) | 65 [50–93] | 63 [48–70] | 67 [50–100] | 0.22 |
SOFA score | 4 [2–7] | 2 [2, 3] | 5 [2–7] | 0.003 |
Nonsteroidal anti-inflammatory drugs (%) | 1 (1%) | 0 (0) | 1 (1%) | 1.00 |
Invasive mechanical ventilation | 55 (55%) | 6 (32%) | 49 (61%) | 0.04 |
PEEP at day 1 | 0 [0–10] | 0 [0–4] | 8 [0–10] | 0.04 |
Renal replacement therapy | 13 (13%) | 0 (0) | 13 (16%) | 0.14 |
Vasopressors | 51 (51%) | 7 (37%) | 44 (55%) | 0.24 |
IL6 at day 0 (ng/mL) | 118 [67–287] | 136 [63–292] | 113 [69–287] | 0.98 |
C3 at day 0 (ng/mL) | 1305 [1173–1550] | 1495 [1285, 1630] | 1260 [1160–1543] | 0.06 |
C4 at day 0 (ng/mL) | 348 [275–418] | 351 [282–493] | 348 [272–416] | 0.69 |
sC5b9 at day 0 (ng/mL) | 373 [270–471] | 425 [317–516] | 363 [266–450] | 0.22 |
Ferritin at day 0 (mg/L) | 1272 [636–2234] | 1182 [495–1584] | 1311 [695–2322] | 0.12 |
Fibrinogen at day 0 (g/L) | 6.8 [5.8–7.8] | 7.2 [5.4–7.7] | 6.7 [5.8–7.8] | 0.94 |
Acute kidney injury - | 81 (81%) | 0 (0) | 81 (100%) | < 0.001 |
KDIGO stage | < 0.001 | |||
No AKI | 19 (19%) | 19 (100%) | 0 (0) | |
Stage 1 | 44 (44%) | 0 (0) | 44 (54%) | |
Stage 2 | 10 (10%) | 0 (0) | 10 (12%) | |
Stage 3 | 27 (27%) | 0 (0) | 27 (33%) | |
KDIGO criteria fulfilled | < 0.001 | |||
Creatinine criteria alone | 28 (28%) | 0 (0) | 28 (35%) | |
Oliguria alone | 33 (33%) | 0 (0) | 33 (41%) | |
Both criteria | 20 (20%) | 0 (0) | 20 (25%) | |
None | 19 (19%) | 19 (100%) | 0 (0) | |
Day-28 mortality | 29 (29%) | 1 (5%) | 28 (35%) | 0.02 |
Specific treatment during ICU stay | 0.35 | |||
Chloroquine or Hydroxychloroquine | 3 (3%) | 0 (0) | 3 (4%) | |
Eculizumab | 2 (2%) | 0 (0) | 2 (3%) | |
Lopinavir/ritonavir | 10 (10%) | 0 (0) | 10 (12%) | |
Tocilizumab | 1 (1%) | 0 (0) | 1 (1%) | |
None | 84 (84%) | 19 (100%) | 65 (80%) |